Market News Latest

Gastroesophageal Adenocarcinoma Market Size and Trends Analysis, Clinical and Commercial Assessment of the Pipeline Therapies, Leading Companies, and Epidemiology Forecast

 Breaking News
  • No posts were found

Gastroesophageal Adenocarcinoma Market Size and Trends Analysis, Clinical and Commercial Assessment of the Pipeline Therapies, Leading Companies, and Epidemiology Forecast

July 20
18:22 2021
Gastroesophageal Adenocarcinoma Market Size and Trends Analysis, Clinical and Commercial Assessment of the Pipeline Therapies, Leading Companies, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Gastroesophageal Adenocarcinoma Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Gastroesophageal Adenocarcinoma Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Gastroesophageal Adenocarcinoma Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Gastroesophageal Adenocarcinoma market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Gastroesophageal Adenocarcinoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Gastroesophageal Adenocarcinoma Market


Gastroesophageal junction adenocarcinoma begins in the glandular cells located near the GE junction and has also been referred to as ‘esophagogastric junction adenocarcinoma’. The risk factors of the disease include Gastroesophageal reflux disease and Barrett’s esophagus and others along with this smoking and tobacco use also increase the risk.

Common symptoms and signs of Gastroesophageal adenocarcinoma include difficulty or pain with swallowing and unintentional weight loss, cough, nausea and vomiting, and others. Treatment of locally advanced GEJ tumors presents a unique challenge because these tumors have generally been approached as either esophageal or gastric.

Gastroesophageal Adenocarcinoma Market Key Facts

  • Population-based studies in several western countries have shown that the incidence of esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (GEJAC) has rapidly increased; however, the degree of increment of EAC was less than that of the GEJAC (Walther C et. al,2001)

  • The Surveillance, Epidemiology and End Results (SEER) cancer registry program in the United States demonstrated an approximately 2.5-fold increase in the incidence of GEJAC from 1973 to 1992, from 1.22 cases per 100,000 individuals (1973-1978) to 2.00 cases per 100,000 individuals (1985-1990), with rates stabilizing in the last two decades, with an incidence of 1.94 cases per 100,000 individuals (2003-2008) (Buas MF et. al)

  • Based on literature review, numbers of adenocarcinomas classified at cardia or in distal esophagus in the Osaka registry of Japan in 1980-93 were 2,151 and 15; while in the registries of 4 regions in France in 1978-92, the respective numbers were 2,203 and 358 (Lambert, n.d.).

Key Benefits of Gastroesophageal Adenocarcinoma Market Report

  • The market report provides an in-depth analysis of Gastroesophageal Adenocarcinoma Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Gastroesophageal Adenocarcinoma Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Gastroesophageal Adenocarcinoma current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Gastroesophageal Adenocarcinoma market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Get FREE sample copy at:

Gastroesophageal Adenocarcinoma Market 

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Gastroesophageal Adenocarcinoma market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Gastroesophageal Adenocarcinoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Gastroesophageal Adenocarcinoma Epidemiology

The epidemiology section covers insights about the historical and current Gastroesophageal Adenocarcinoma patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Gastroesophageal Adenocarcinoma Epidemiology Subtype Segmentation

  • Total incidence of Gastroesophageal Junction Adenocarcinoma

  • Gender-specific cases of Gastroesophageal Junction Adenocarcinoma 

  • Biomarker-specific cases of Gastroesophageal Junction Adenocarcinoma

Gastroesophageal Adenocarcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroesophageal Adenocarcinoma market or expected to get launched in the market during the study period. The analysis covers Gastroesophageal Adenocarcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Gastroesophageal Adenocarcinoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Request for Sample @ Gastroesophageal Adenocarcinoma Market Outlook

Table of Content

1. Key Insights

2. Executive Summary 

3. Gastroesophageal Adenocarcinoma Competitive Intelligence Analysis

4. Gastroesophageal Adenocarcinoma Market Overview at a Glance

5. Gastroesophageal Adenocarcinoma Disease Background and Overview

6. Gastroesophageal Adenocarcinoma Patient Journey

7. Gastroesophageal Adenocarcinoma Epidemiology and Patient Population

8. Gastroesophageal Adenocarcinoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Gastroesophageal Adenocarcinoma Unmet Needs

10. Key Endpoints of Gastroesophageal Adenocarcinoma Treatment

11. Gastroesophageal Adenocarcinoma Marketed Products

12. Gastroesophageal Adenocarcinoma Emerging Therapies

13. Gastroesophageal Adenocarcinoma Seven Major Market Analysis

14. Attribute Analysis

15. Gastroesophageal Adenocarcinoma Market Outlook (7 major markets)

16. Gastroesophageal Adenocarcinoma Access and Reimbursement Overview

17. KOL Views on the Gastroesophageal Adenocarcinoma Market.

18. Gastroesophageal Adenocarcinoma Market Drivers

19. Gastroesophageal Adenocarcinoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

Latest Blogs By DelveInsight

Cardiac Monitoring Devices Market Growth

As per DelveInsight, the rising incidence of cardiovascular conditions, increasing demand for innovative devices, and technological advancements are expected to drive the growth of the Cardiac Monitoring Devices Market in the coming years. Some of the key companies in the Cardiac Monitoring Devices Market include Medtronic, Boston Scientific, Abbott, GE Healthcare, BIOTRONIK, MicroPort, Nihon Kohden America, SCHILLER, BPL Medical Technologies, ACS Diagnostics, Shenzhen Mindray Bio-Medical Electronics, Lepu Medical Technology, Shree Pacetronix, Metrax GmbH, among others.

JAK Inhibitors Companies

As per the DelveInsight, JAK Inhibitors Pipeline is expected to be fuelled by rising prescription demand, however side effects, safety issues, regulatory clearances, and labeling restrictions are the key concerns hampering their growth. Currently, some of the key companies investing in the JAK Inhibitors Portfolio to advance the market share includes Eli Lilly and Company, Astellas Pharma US, Pfizer, Baxter International Inc., Novartis, AbbVie, Sierra Oncology, CTI BioPharma, Incyte, and others.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States